Literature DB >> 31529391

A clinical prediction score using age at diagnosis and saline infusion test parameters can predict aldosterone-producing adenoma from idiopathic adrenal hyperplasia.

H T Leung1, Y C Woo2, C H Y Fong2, K C B Tan2, E Y F Lau3, K W Chan4, J Y Y Leung5.   

Abstract

PURPOSE: Accurate subtyping of the primary aldosteronism into aldosterone-producing adenoma (APA) and idiopathic adrenal hyperplasia (IAH) is important to direct for specific treatment modalities. The objective of the study was to compare the clinical and biochemical parameters of APA and IAH patients to derive a Clinical Prediction Score reliably predicting APA from IAH.
METHODS: This was a retrospective multi-centre study recruiting 38 APA patients and 42 IAH patients from four major hospitals in Hong Kong using database from Surgical Outcomes Monitoring and Improvement Programme and Clinical Data Analysis and Reporting System. Their clinical and biochemical parameters were evaluated.
RESULTS: Patients in APA group were younger than IAH group (mean age 48.6 ± 9.2 vs. 57.1 ± 7.3 years old, p < 0.001), had more suppressed renin before saline infusion in saline infusion test (SIT) (median 0.19 [IQR 0.15-0.37] vs. 0.39 [IQR 0.19-0.69] ng/mL/h, p = 0.01), and higher aldosterone level after saline infusion in SIT (median 674 [IQR 498-1000] vs. 327 [IQR 242-483] pmol/L, p < 0.001). A clinical prediction score using three parameters was devised, comprising age at diagnosis < 50 years, PRA before saline infusion in SIT ≤ 0.26 ng/mL/h, and aldosterone level after saline infusion in SIT ≥ 424 pmol/L. A score of 2 would predict APA with a sensitivity of 84.2% and specificity of 88.1%, and a score of 3 would predict APA with a sensitivity of 31.6% and specificity of 100%.
CONCLUSIONS: Clinical Prediction Score based on the combination of age at diagnosis, PRA, and aldosterone level in the saline infusion tests could reliably predict APA from IAH.

Entities:  

Keywords:  Adrenal adenoma; Adrenal hyperplasia; Clinical prediction; Primary aldosteronism; Saline infusion test

Mesh:

Substances:

Year:  2019        PMID: 31529391     DOI: 10.1007/s40618-019-01114-6

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  37 in total

1.  Aldosterone-to-renin ratio as a screening test for primary aldosteronism--the Dutch ARRAT Study.

Authors:  P M Jansen; F Boomsma; A H van den Meiracker
Journal:  Neth J Med       Date:  2008-05       Impact factor: 1.422

2.  Comparison of left ventricular structure and function in primary aldosteronism and essential hypertension by echocardiography.

Authors:  Yan Yang; Li-Min Zhu; Jian-Zhong Xu; Xiao-Feng Tang; Ping-Jin Gao
Journal:  Hypertens Res       Date:  2016-10-13       Impact factor: 3.872

3.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.

Authors:  Paul Milliez; Xavier Girerd; Pierre-François Plouin; Jacques Blacher; Michel E Safar; Jean-Jacques Mourad
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

4.  Observational study mortality in treated primary aldosteronism: the German Conn's registry.

Authors:  Martin Reincke; Evelyn Fischer; Sabine Gerum; Katrin Merkle; Sebastian Schulz; Anna Pallauf; Marcus Quinkler; Gregor Hanslik; Katharina Lang; Stefanie Hahner; Bruno Allolio; Christa Meisinger; Rolf Holle; Felix Beuschlein; Martin Bidlingmaier; Stephan Endres
Journal:  Hypertension       Date:  2012-07-23       Impact factor: 10.190

Review 5.  Prevalence of primary aldosteronism in patient's cohorts and in population-based studies--a review of the current literature.

Authors:  A Hannemann; H Wallaschofski
Journal:  Horm Metab Res       Date:  2011-12-01       Impact factor: 2.936

6.  Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I.

Authors:  Michael Stowasser; James Sharman; Rodel Leano; Richard D Gordon; Gregory Ward; Diane Cowley; Thomas H Marwick
Journal:  J Clin Endocrinol Metab       Date:  2005-06-07       Impact factor: 5.958

7.  A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.

Authors:  Gian Paolo Rossi; Giampaolo Bernini; Chiara Caliumi; Giovambattista Desideri; Bruno Fabris; Claudio Ferri; Chiara Ganzaroli; Gilberta Giacchetti; Claudio Letizia; Mauro Maccario; Francesca Mallamaci; Massimo Mannelli; Mee-Jung Mattarello; Angelica Moretti; Gaetana Palumbo; Gabriele Parenti; Enzo Porteri; Andrea Semplicini; Damiano Rizzoni; Ermanno Rossi; Marco Boscaro; Achille Cesare Pessina; Franco Mantero
Journal:  J Am Coll Cardiol       Date:  2006-11-13       Impact factor: 24.094

Review 8.  Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension.

Authors:  George Piaditis; Athina Markou; Labrini Papanastasiou; Ioannis I Androulakis; Gregory Kaltsas
Journal:  Eur J Endocrinol       Date:  2014-12-23       Impact factor: 6.664

9.  Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study.

Authors:  Sébastien Savard; Laurence Amar; Pierre-François Plouin; Olivier Steichen
Journal:  Hypertension       Date:  2013-06-10       Impact factor: 10.190

10.  Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism.

Authors:  Giampaolo Bernini; Fabio Galetta; Ferdinando Franzoni; Michele Bardini; Chiara Taurino; Melania Bernardini; Lorenzo Ghiadoni; Matteo Bernini; Gino Santoro; Antonio Salvetti
Journal:  J Hypertens       Date:  2008-12       Impact factor: 4.844

View more
  2 in total

1.  Validation of three novel clinical prediction tools for primary aldosteronism subtyping.

Authors:  Tomaž Kocjan; Gaj Vidmar; Peter Popović; Milenko Stanković
Journal:  Endocr Connect       Date:  2022-05-11       Impact factor: 3.221

Review 2.  Recent Development toward the Next Clinical Practice of Primary Aldosteronism: A Literature Review.

Authors:  Yuta Tezuka; Yuto Yamazaki; Yasuhiro Nakamura; Hironobu Sasano; Fumitoshi Satoh
Journal:  Biomedicines       Date:  2021-03-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.